|Bid||1.0100 x 1200|
|Ask||1.0500 x 4000|
|Day's range||1.0000 - 1.0950|
|52-week range||1.0000 - 2.6500|
|Beta (5Y monthly)||2.25|
|PE ratio (TTM)||N/A|
|Earnings date||02 Aug 2023 - 07 Aug 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||5.58|
The heavy selling pressure might have exhausted for Adaptimmune Therapeutics PLC (ADAP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Sweetgreen, Adaptimmune Therapeutics, Owl Rock Capital, MACOM Technology Solutions and Equity Commonwealth have been highlighted in this Screen of The Week article.
Adaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its proprietary T-cell therapy programs. Shares of the company surges 7% following the news.
Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) were up as much as 9.7% early Tuesday after the clinical-stage biotech announced that it had reached an agreement with GSK (NYSE: GSK) to return the rights to Adaptimmune's PRAME and NY-ESO cell therapy programs. Adaptimmune focuses on therapies to treat cancer in solid tumors through its SPEAR (for Specific Peptide Enhanced Affinity Receptor) T-cell platform. The company has four SPEAR T-cells in trials: MAGE-A10, MAGE-A4, AFP, and NY-ESO.
Mesa Labs and Eldorado Gold are part of the Zacks Bull and Bear of the Day article.
We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.
Shares of the anti-cancer cell therapy company Adaptimmune Therapeutics (NASDAQ: ADAP) are having an unusually strong showing today. Ahead of the opening bell, Adaptimmune released both its third-quarter earnings and a clinical program update for its MAGE-A4 franchise. In an exploratory study of patients with various solid tumors, the company's modified T-cell therapy, known as ADP-A2M4CD8, reportedly produced an overall response rate of 43% in patients with advanced ovarian cancer.
Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.
Shares of the British cell therapy company Adaptimmune Therapeutics (NASDAQ: ADAP) are having one of their best days in several months today. To put this move into the proper context, the bellwether biotech indices -- the iShares Biotechnology ETF and the SPDR S&P Biotech ETF -- are both essentially flat for the day at the time of this writing. Adaptimmune's shares appear to be perking up in response to the buyout of fellow soft tissue cancer specialist Epizyme (NASDAQ: EPZM) earlier today.